The company secured warrant amendments that align with an anticipated near-term FDA approval milestone, potentially raising up to $11 million to support product launch. The CGUARDIANS II study showed strong clinical results (100% acute device success, zero major adverse events), and the expansion into TCAR procedures doubles the addressable market. However, the positive sentiment is tempered by the company's history of losses, ongoing recall issues, and dependence on regulatory approval.
The company achieved a significant milestone with first patient enrollment in a pivotal study for its next-generation neuro protection system. The study represents advancement in their product portfolio and addresses a growing market (estimated 70,000 TCAR procedures annually by 2030). Additionally, Q1 2026 showed strong revenue growth of 122% year-over-year, demonstrating commercial traction alongside clinical progress.
Also mentions NSPR
Articles that tag NSPR but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
